MCE 的所有產品僅用作科學研究或藥證申報，我們不為任何個人用途提供產品和服務。

Ibuprofen

產品活性：Ibuprofen ((±)-Ibuprofen) 是一種口服有效的 COX-1 選擇性抑制劑，IC₅₀ 值為 13 μM。Ibuprofen 抑制細胞增殖、血管生成，并誘導細胞凋亡 (apoptosis)。Ibuprofen 是一種非甾體抗炎試劑和一氧化氮 (NO) 供體。Ibuprofen可用于疼痛、腫脹、炎癥、感染、免疫學、癌癥的研究。

研究領域：Immunology/Inflammation  |  Apoptosis  |  Anti-infection

作用靶點：COX  |  Apoptosis  |  Parasite

In Vitro: Ibuprofen (24 h) inhibits COX-1 and COX-2 activity with IC₅₀ values of 13 μM and 370 μM.
Ibuprofen (500 μM, 48 h) inhibits cell proliferation and angiogenesis, and induces apoptosis in AGS cells (Adenocarcinoma gastric cell line).
Ibuprofen (500 μM, 48 h) downregulates transcription of Akt, VEGF-A, PCNA, Bcl2, OCT3/4 and CD44 genes, but upregulates RNA levels of wild type P53 and Bax genes in AGS cell.
Ibuprofen (500 μM, 24 h) restores microtubule reformation, microtubule-dependent intracellular cholesterol transport, and induces extension of microtubules to the cell periphery in both cystic fibrosis (CF) cell models and primary CF nasal epithelial cells.
Ibuprofen (500 μM, 24 h) enhances UV-induced cell death in MCF-7 cells and MDA-MB-231 cells by a photosensitization process.

In Vivo: Ibuprofen (300 mg/kg; p.o.; daily, for 14 days) reduces overall tumor growth and enhances anti-tumor immune characteristics without adverse autoimmune reactions in a model of postpartum breast cancer.
Ibuprofen (60 mg/kg; i.h.; every second day for 15 days) reduces the risk of neuropathy in a rat model of chronic Oxaliplatin?induced peripheral neuropathy.
Ibuprofen (20 mg/kg; p.o.; every 12 hours, 5 doses total) decreases muscle growth (average muscle fiber cross-sectional area) without affecting regulation of supraspinatus tendon adaptions to exercise.
Ibuprofen (35 mg/kg; p.o.; twice daily) attenuates the Inflammatory response to pseudomonas aeruginosa in a rat model of chronic pulmonary infection.

相關產品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Immunology/Inflammation Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  CNS-Penetrant Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Pyroptosis Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Breast Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Antiparasitic Compound library  |  Anti-Obesity Compound Library  |  Targeted Diversity Library  |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  Children’s Drug Library  |  Antidepressant Compound Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Withdrawn Drug Compound Library  |  Off-patent Drug Library  |  SY-5609  |  Antifungal agent 26  |  BRD4 Inhibitor-18  |  8α-Tigloyloxyhirsutinolide 13-O-acetate  |  Quinidine-d₃  |  Angulatin G  |  Acridine Orange base  |  N-Desethyl amodiaquine-d₅  |  Palitantin  |  AAPK-25  |  Dutasteride-¹³C₆  |  Oleic acid-¹³C  |  Proguanil-d₆  |  Azlocillin sodium salt  |  Abacavir sulfate  |  Meloxicam-d₃-1  |  4-Methylamino antipyrine hydrochloride  |  Thailanstatin D  |  SB-218078  |  Vedaprofen-d₃  |  Toyocamycin  |  Methyl palmitate  |  Sorafenib-d₄  |  Pelubiprofen-¹³C,d₃  |  Busulfan  |  PTC-028  |  Dinaciclib  |  CR-1-31-B  |  HBPC–GSH

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫，我們致力于為*科研客戶提供前沿的高品質小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領；
•   產品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產品，廣泛應用于新藥研發(fā)、生命科學等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學分析檢測分析，藥物篩選等專業(yè)技術服務；
•   設有專業(yè)的實驗中心和嚴格的質控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質檢報告，確保產品的高純度、高品質；
•   產品的生物活性多經各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團隊跟蹤新的制藥及生命科學研究進展，為您提供*新的活性化合物；
•   與世界各大制藥公司及*科研機構建立了長期的合作。